Imagine cancer cells have a 'do not disturb' sign that stops the body's immune system from attacking them. This drug removes that sign and simultaneously wakes up the immune cells to start fighting the tumor. It acts like a triple-action key that unlocks the body's natural ability to destroy advanced tumors.
Many cancer patients are refractory to current PD1 therapies, leaving a massive unmet need in the 80 billion euro immuno-oncology market for treatments that can overcome tumor-driven immune suppression.
A first-in-class monoclonal antibody (NTX1088) and a clinical trial infrastructure across the US, Israel, and Poland.
If you are a drug developer dealing with patients who no longer respond to standard PD1 therapies — this project developed NTX1088 that showed activity in heavily pretreated patients, including 1 complete response and 5 partial responses in a combination group.
If you are a clinic dealing with advanced solid malignancies that are hard to treat — this project developed a first-in-class antibody that can be used as a monotherapy or combined with pembrolizumab to improve patient outcomes.
If you are a CRO dealing with the need for new EU-based clinical trial sites — this project developed a regulatory pathway via CTIS and established an active enrollment site at the Maria Sklodowska Curie National Research Institute of Oncology.
Based on available project data, the specific cost or pricing for NTX1088 is not disclosed.
The project is currently in Phase 1 clinical trials with dose escalation up to 1750 mg, but industrial manufacturing scale details are not provided.
Based on available project data, the drug is developed by Nectin Therapeutics Ltd, a venture-backed company, though specific patent numbers are not listed.
The company has already engaged with the European Medicines Agency via CTIS and has an active site in Poland for patient enrollment.
NTX1088 is designed to work as a monotherapy or in combination with pembrolizumab, showing potential for combined antitumor responses.
The project is led by a single partner, Nectin Therapeutics Ltd, an Israeli SME. This 100% industry-led structure indicates a high level of commercial drive and streamlined decision-making, typical of venture-backed biotech firms moving rapidly through clinical trial phases.
Contact Nectin Therapeutics Ltd in Israel
Contact us to explore licensing or partnership opportunities for PVR-targeting therapies.
